Autosomal dominant polycystic kidney disease MedDRA version: 20.0 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850
Conditions
Interventions
Product Name: GLPG2737
Product Code: G1117337
Pharmaceutical Form: Capsule
INN or Proposed INN: Not applicable
Current Sponsor code: G1117337
Other descriptive name: GLPG2737
Concentration unit: mg mi
Sponsors
Galapagos NV
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Main inclusion criteria for the double-blind period of the study: 1. Male and female subject aged 18 to 50 years, inclusive. 2. Documented diagnosis of typical ADPKD, using the Ravine criteria. 3. Rapidly progressive disease, defined as presence of all of the following: -TKV >750 mL, as determined on imaging not older than 5 years before screening. If historical imaging is not available or older than 5 years, imaging can be performed during the screening period according to local clinical practice (i.e. echography, magnetic resonance imaging [MRI]). -Mayo ADPKD Classification Classes 1C to 1E. 4. eGFR at screening between 30-90 mL/min/1.73 m2 for subjects aged 18 to 40 years (inclusive), and between 30-60 mL/min/1.73 m2 for subjects aged 40 to 50 years. 5. Blood pressure = 150/90 mmHg. In case the subject is treated for hypertension, he/she should be on a stable treatment regimen of antihypertensive therapy for at least 8 weeks prior to the screening visit, and during the screening period. Main inclusion criteria for the open-label extension period of the study: 1. Male and female subjects who completed the 52-week double-blind treatment period on IP. 2. Subject, according to the investigator's judgement, may benefit from long-term treatment with GLPG2737. Reference is made to the protocol for a complete overview of the inclusion criteria. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: Main exclusion criteria for the double-blind period of the study: 1. Congenital absence of 1 kidney, or subject had a previous nephrectomy or has a transplanted kidney or a transplantation is planned in the foreseeable future. 2. Administration of polycystic kidney disease-modifying agents (e.g. tolvaptan, somatostatin analogues) or interventions (such as cyst aspiration or cyst fenestration) within 12 weeks prior to the screening visit and during the screening period. In case tolvaptan is not being administered, this should be because of e.g. non-availability, intolerance, or physician’s clinical judgment. 3. Any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements (e.g. unable to undergo MRI. For example subject's weight exceeds weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, etc.). Main exclusion criterion for the open-label extension period of the study: 1. Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction, QTcF > 450 ms, or long QT syndrome. Reference is made to the protocol for a complete overview of the exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - To characterize the effect of GLPG2737 on growth in total kidney volume (TKV) compared to placebo. - To evaluate the safety and tolerability of oral doses of GLPG2737 compared to placebo. ;Secondary Objective: - To characterize the effect of GLPG2737 on renal function (estimated glomerular filtration rate; eGFR) compared to placebo. - To characterize the pharmacokinetics (PK) of oral doses of GLPG2737 and its major metabolite G1125498 (M4) using population PK analyses.;Primary end point(s): - Mean percent change from baseline of height-adjusted TKV (htTKV). - Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious AEs (SAEs), and TEAEs leading to treatment discontinuation. ;Timepoint(s) of evaluation of this end point: Various timepoints throughout the trial from baseline until the end of the double-blind period as specified in the protocol. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Mean change from baseline estimated GFR (eGFR). - Estimated exposure (area under the curve [AUC], maximum plasma concentration [Cmax]), based on population PK analyses of GLPG2737 and its major metabolite M4. ;Timepoint(s) of evaluation of this end point: Various timepoints throughout the trial from baseline until the end of the double-blind period as specified in the protocol. | — |
Countries
Belgium, Czech Republic, Germany, Italy, Netherlands, Spain
Contacts
Public ContactGalapagos Medical Information
Galapagos NV
Outcome results
None listed